Mode
Text Size
Log in / Sign up

Cross-Sectional Study Shows Rising PPI Use in Chinese ACS and AF Patients at DischargeWhy are nearly two-thirds of heart patients now getting stomach acid blockers at discharge?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note increasing PPI prescription rates in Chinese ACS and AF patients, though safety and outcomes are not reported.

This cross-sectional study analyzed prescription patterns among 531 Chinese patients diagnosed with acute coronary syndrome and atrial fibrillation. The research was conducted at the Cardiovascular Center of Beijing Tongren Hospital. The primary objective was to evaluate trends and influencing factors regarding proton pump inhibitor administration at discharge. No specific follow-up duration was reported for this observational analysis. Results spanned 2010 to 2018.

The study compared patients receiving proton pump inhibitor administration at discharge against a non-PPI group. Results indicated an increasing trend in PPI administration rates over time. Specifically, the rate rose from 21.3% during the 2010–2012 period to 63.5% during the 2016–2018 period. Overall, 47.8% of the cohort, representing 254 out of 531 patients, received a proton pump inhibitor. The p-value associated with the trend is listed as p in the source data. Prescribing behavior shifted significantly during the study period.

Safety data were not reported in this analysis. Adverse events, serious adverse events, discontinuations, and tolerability information were not reported. The study limitations were not explicitly detailed in the provided input. As a cross-sectional design, this evidence describes associations rather than causal relationships between PPI use and clinical outcomes. Practice relevance is limited by the lack of outcome data beyond prescription patterns. Clinicians should interpret these findings as descriptive trends within a specific hospital setting rather than generalizable guidelines. Generalizability is restricted to this single center.

Imagine walking out of the hospital with a heart condition and being handed a new daily pill for your stomach. That is exactly what happened to many patients in a recent look at medical records at Beijing Tongren Hospital. The researchers found that giving stomach acid blockers, known as proton pump inhibitors, became much more common over time. In the early years, only about 21% of patients received them. By the late years, that number climbed to 64%. Overall, nearly half of all patients in this group got the medication.

The study looked at people with acute coronary syndrome, which includes heart attacks, and atrial fibrillation, a type of irregular heartbeat. These are serious conditions that require careful management. The doctors in this group were increasingly choosing to add these stomach medicines when sending patients home. The data shows a clear trend of increasing use, but the study did not find any reported safety issues, serious side effects, or reasons patients had to stop taking the drugs.

This change in practice is significant because it reflects how medical habits evolve. However, because this was a snapshot of records rather than a long-term experiment, we cannot say for sure if these drugs improve heart health or cause hidden problems. The study simply tells us that doctors are prescribing them much more often now. Patients should talk to their own doctors about whether this specific medication is right for their unique situation and medical history.

What this means for you:
Stomach acid blocker use for heart patients rose sharply from 2010 to 2018, though the study did not prove they help or hurt recovery.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThe real-world status of proton pump inhibitor (PPI) administration in patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) remains largely unknown.ObjectivesThis study aimed to analyze the prescription pattern, trends and influencing factors of PPIs among Chinese patients with ACS and AF at discharge.MethodsThis single-center, retrospective, cross-sectional study included patients with ACS and AF who were hospitalized at the Cardiovascular Center of Beijing Tongren Hospital from January 2010 to December 2018. All patients were subsequently categorized into two groups based on PPI administration at discharge (i.e., the PPI and non-PPI group), after which factors influencing PPI use were analyzed.ResultsThis study included 531 patients diagnosed with ACS and AF, with a median age of 73 years, 61.4% of these patients were male. Among them, 254 patients (47.8%) were administered PPIs. A significant increasing trend in PPI administration was observed from 21.3% (2010–2012) to 63.5% (2016–2018) (p 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.